Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer Invests In Bind Therapeutics

by Ann M. Thayer
April 8, 2013 | A version of this story appeared in Volume 91, Issue 14

Pfizer and Bind Therapeutics will collaborate on the development of Bind’s Accurin therapeutics. The Cambridge, Mass.-based biotech firm uses “medicinal nanoengineering” to create drug-carrying particles targeted for specific tissues and cells. For an exclusive option to develop and commercialize selected Accurins, Pfizer will pay about $50 million in up-front and development fees along with another $160 million for achieving regulatory and sales milestones for each Accurin. Bind also has a $180 million deal with Amgen for a kinase inhibitor. Bind’s technology originates from Massachusetts Institute of Technology and Harvard Medical School.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.